Foghorn Therapeutics (FHTX) Income from Continuing Operations (2019 - 2026)
Foghorn Therapeutics' (FHTX) quarterly Income from Continuing Operations came in at 80642000.0 in Q1 2026, down 250.88% year-on-year from 53448929.69 in Q1 2025, and down 238.14% quarter-over-quarter from 23849000.0 in Q4 2025.
Foghorn Therapeutics (FHTX) Income from Continuing Operations (2019 - 2026) Analysis & Trends
Foghorn Therapeutics' Income from Continuing Operations history runs 8 years deep, the most recent figure standing at 80642000.0 for Q1 2026.
- On a quarterly basis, Income from Continuing Operations fell 250.88% year-over-year to 80642000.0 in Q1 2026; TTM through Mar 2026 was 226030000.0, a 167.22% decrease from a year earlier, with the FY2025 full-year figure at 265279000.0, down 206.26% from the prior year.
- Income from Continuing Operations fell to 80642000.0 in Q1 2026 per FHTX's latest filing, from 23849000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 14345000.0 in Q3 2023 and bottomed at 80642000.0 in Q1 2026.
- The 5-year median for Income from Continuing Operations is 25769000.0 (2022), against an average of 31937705.88.
- Across the five-year window, Income from Continuing Operations jumped 74.31% in 2022 and sank 250.88% in 2026, its largest moves.
- Year by year, Income from Continuing Operations stood at 28886000.0 in 2022, then grew by 16.55% to 24106000.0 in 2023, then climbed by 19.09% to 19503000.0 in 2024, then dropped by 22.28% to 23849000.0 in 2025, then tumbled by 238.14% to 80642000.0 in 2026.
- Per Business Quant, the three latest FHTX Income from Continuing Operations figures stand at 80642000.0 (Q1 2026), 23849000.0 (Q4 2025), and 41751000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Foghorn Therapeutics | 352.57 Mn | 263.66 Mn | - | -80.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -80.64 Mn |
| Dec 31, 2025 | -23.85 Mn |
| Sep 30, 2025 | -41.75 Mn |
| Jun 30, 2025 | -79.79 Mn |
| Mar 31, 2025 | -22.98 Mn |
| Dec 31, 2024 | -19.50 Mn |
| Sep 30, 2024 | -19.12 Mn |
| Jun 30, 2024 | -22.98 Mn |
| Mar 31, 2024 | -25.02 Mn |
| Dec 31, 2023 | -24.11 Mn |
| Sep 30, 2023 | -14.35 Mn |
| Jun 30, 2023 | -29.49 Mn |
| Mar 31, 2023 | -30.49 Mn |
| Dec 31, 2022 | -28.89 Mn |
| Sep 30, 2022 | -25.77 Mn |
| Jun 30, 2022 | -27.31 Mn |
| Mar 31, 2022 | -26.91 Mn |
| Dec 31, 2021 | -36.60 Mn |
| Sep 30, 2021 | -100.32 Mn |
| Jun 30, 2021 | -99.79 Mn |